These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 19750117)

  • 1. FDA's Janet Woodcock Riding High: CDER Director Wins "Wows" Amid Agency Woes.
    Barlas S
    P T; 2008 Jul; 33(7):396-7. PubMed ID: 19750117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interview with Janet Woodcock: progress on the FDA's critical path initiative.
    Woodcock J
    Biomark Med; 2009 Dec; 3(6):671-3. PubMed ID: 20477704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interview with Janet Woodcock.
    Woodcock J
    Bioanalysis; 2010 Sep; 2(9):1535-8. PubMed ID: 21083281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generic Pharmaceutical Association (GPhA) - 2015 CMC Workshop (June 9-10, 2015 - Bethesda, Maryland, USA).
    Komlos D
    Drugs Today (Barc); 2015 Jul; 51(7):429-40. PubMed ID: 26261845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Janet Woodcock discusses the FDA and the drug development process. Interview by Christopher Watson.
    Woodcock J
    Drug Discov Today; 2004 Jul; 9(13):548-50. PubMed ID: 15203087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New FDA Center May Speed Approval Process.
    Cancer Discov; 2016 Sep; 6(9):OF5. PubMed ID: 27417310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA'S food ingredient approval process: Safety assurance based on scientific assessment.
    Rulis AM; Levitt JA
    Regul Toxicol Pharmacol; 2009 Feb; 53(1):20-31. PubMed ID: 18983884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complexities in drug trials: enrichment, biomarkers and surrogates. Interview with Robert Temple.
    Temple R
    Biomark Med; 2008 Apr; 2(2):109-12. PubMed ID: 20477432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An FDA Analysis of Formal Dispute Resolution in the Center for Drug Evaluation and Research: 2003 Through 2014.
    Sharma K; Harrington A; Worrell S; Bertha A
    Ther Innov Regul Sci; 2016 Nov; 50(6):697-704. PubMed ID: 30231744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Piloting social engagement on a federal agency-administered Facebook page.
    Chiu K; Wagner L; Choe L; Chew C; Kremzner M
    J Am Pharm Assoc (2003); 2016; 56(3):330-7. PubMed ID: 27079138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ten-Year Experience for the Center for Drug Evaluation and Research, Part 2: FDA's Role in Ensuring Patient Safety.
    Jarow JP; Lemery S; Bugin K; Lowy N
    Ther Innov Regul Sci; 2017 Mar; 51(2):246-249. PubMed ID: 28553566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The FDA's risk/benefit calculus in the approvals of Qsymia and Belviq: treating an obesity epidemic while avoiding another fen-phen.
    Azebu LM
    Food Drug Law J; 2014; 69(1):87-111, ii-iii. PubMed ID: 24772687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expediting drug development--the FDA's new "breakthrough therapy" designation.
    Sherman RE; Li J; Shapley S; Robb M; Woodcock J
    N Engl J Med; 2013 Nov; 369(20):1877-80. PubMed ID: 24224621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Public Knowledge and Credibility Perceptions of the FDA as a Tobacco Regulator.
    Schmidt AM; Jarman KL; Ranney LM; Queen TL; Noar SM; Ruel L; Agans R; Hannan A; Goldstein AO
    Nicotine Tob Res; 2018 Sep; 20(11):1310-1316. PubMed ID: 29059369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paving the critical path of drug development: the CDER perspective.
    Woodcock J
    Nat Rev Drug Discov; 2014 Nov; 13(11):783-4. PubMed ID: 25359359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Center for Drug Evaluation and Research Perspective on Quality in Clinical Trials.
    Shapley S; O'Shaughnessy J; Woodcock J
    Ther Innov Regul Sci; 2017 Jul; 51(4):416-418. PubMed ID: 30227045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human factors and the FDA's goals: improved medical device design.
    Burlington DB
    Biomed Instrum Technol; 1996; 30(2):107-9. PubMed ID: 8673158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advisory committee; Medical Imaging Drugs Advisory Committee; re-establishment.
    Food and Drug Administration, HHS
    Fed Regist; 2011 Jul; 76(146):45402-3. PubMed ID: 21800457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How the Critical Path Initiative Addresses CDER's Regulatory Science Needs: Some Illustrative Examples.
    Geanacopoulos M; Barratt R
    Ther Innov Regul Sci; 2015 Jul; 49(4):466-472. PubMed ID: 30222436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.